Drug Profile
RC 3095
Alternative Names: D 21663; RC-3095Latest Information Update: 12 Sep 2007
Price :
$50
*
At a glance
- Originator Tulane University
- Developer AEterna Zentaris Inc
- Class Antineoplastics
- Mechanism of Action Gastrin-releasing peptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 04 Aug 2005 This compound is still in active development for Cancer
- 01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris
- 11 Jul 2003 Phase-II clinical trials in Cancer in USA (unspecified route)